Flt-1-Dependent Survival Characterizes the Epithelial-Mesenchymal Transition of Colonic Organoids

Aberrant cell survival and resistance to apoptosis are hallmarks of tumor invasion and progression to metastatic disease, but the mechanisms involved are poorly understood. The epithelial-mesenchymal transition (EMT), a process that facilitates progression to invasive cancer, provides a superb model for studying such survival mechanisms. Here, we used a unique spheroid culture system that recapitulates the structure of the colonic epithelium and undergoes an EMT in response to cytokine stimulation to study this problem. Our data reveal that the EMT results in the increased expression of both VEGF and Flt-1, a tyrosine kinase VEGF receptor, and that the survival of these cells depends on a VEGF/Flt-1 autocrine pathway. Perturbation of Flt-1 function by either a blocking antibody or adenoviral expression of soluble Flt-1, which acts in a dominant-negative fashion, caused massive apoptosis only in cells that underwent EMT. This pathway was critical for the survival of other invasive colon carcinoma cell lines, and we observed a correlative upregulation of Flt-1 expression linked to in vivo human cancer progression. A role for Flt-1 in cell survival is unprecedented and has significant implications for Flt-1 function in tumor progression, as well as in other biological processes, including angiogenesis and development.

[1]  D. Nettelbeck,et al.  Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  R. Warren,et al.  Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. , 1995, The Journal of clinical investigation.

[3]  J. Minna,et al.  Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. , 2000, Cancer research.

[4]  T. Noda,et al.  Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. , 2001, Cancer research.

[5]  A. Ishida,et al.  Expression of vascular endothelial growth factor receptors in smooth muscle cells , 2001, Journal of cellular physiology.

[6]  A. Mercurio,et al.  Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. , 2003, Molecular biology of the cell.

[7]  M. Jäättelä,et al.  Escaping cell death: survival proteins in cancer. , 1999, Experimental cell research.

[8]  K. Alitalo,et al.  Signaling angiogenesis and lymphangiogenesis. , 1998, Current opinion in cell biology.

[9]  Thomas N. Sato,et al.  Role of the Ets transcription factors in the regulation of the vascular-specific Tie2 gene. , 1999, Circulation research.

[10]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[11]  A. Casalini,et al.  Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma , 2001, The Journal of pathology.

[12]  R. D'Amato,et al.  Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. Chuang,et al.  Different signal transduction pathways are coupled to the nucleotide receptor and the P2Y receptor in C6 glioma cells. , 1994, The Journal of pharmacology and experimental therapeutics.

[14]  R. Hay,et al.  Intercellular karyotypic similarity in near-diploid cell lines of human tumor origins. , 1983, Cancer genetics and cytogenetics.

[15]  S. Aharinejad,et al.  Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. , 2002, Journal of pediatric surgery.

[16]  B. Zetter,et al.  Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro. , 1999, Microvascular research.

[17]  M. Shibuya,et al.  Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.

[18]  N. Ferrara,et al.  VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism , 2002, Nature.

[19]  S. Natsugoe,et al.  Impact of Vascular Endothelial Growth Factor-C and -D Expression in Human Pancreatic Cancer , 2004, Clinical Cancer Research.

[20]  K. Shitara,et al.  and surface marker for the lineage of monocyte-macrophages in humans Flt-1 , vascular endothelial growth factor receptor 1 , is a novel cell , 2001 .

[21]  G. Martiny-Baron,et al.  Therapies directed at vascular endothelial growth factor , 2002, Expert opinion on investigational drugs.

[22]  B. Wiedenmann,et al.  De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. , 2000, Gastroenterology.

[23]  H. Beug,et al.  TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis , 1998, Current Biology.

[24]  P. Savagner,et al.  Leaving the neighborhood: molecular mechanisms involved during epithelial‐mesenchymal transition , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.

[25]  E. Hay.  An overview of epithelio-mesenchymal transformation. , 1995, Acta anatomica.

[26]  H. Moses,et al.  Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. , 2001, Molecular biology of the cell.

[27]  E. Miyoshi,et al.  Transcriptional Regulation of the N-Acetylglucosaminyltransferase V Gene in Human Bile Duct Carcinoma Cells (HuCC-T1) Is Mediated by Ets-1* , 1996, The Journal of Biological Chemistry.

[28]  J. Vaillant,et al.  Vegf, vegf‐B, vegf‐C and their receptors KDR, FLT‐1 and FLT‐4 during the neoplastic progression of human colonic mucosa , 2000, International journal of cancer.

[29]  K. Inoue,et al.  Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. , 2000, Cancer research.

[30]  J. Winer,et al.  Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. , 1994, The Journal of biological chemistry.

[31]  M. Broggini,et al.  Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4 , 2003, Leukemia.

[32]  S. Arii,et al.  sFlt-1 gene-transfected fibroblasts: a wound-specific gene therapy inhibits local cancer recurrence. , 2001, Cancer research.

[33]  M. Shibuya,et al.  A cAMP Response Element and an Ets Motif Are Involved in the Transcriptional Regulation of flt-1 Tyrosine Kinase (Vascular Endothelial Growth Factor Receptor 1) Gene* , 1996, The Journal of Biological Chemistry.

[34]  H. Hamada,et al.  Gene Therapy for Pancreatic Cancer Using an Adenovirus Vector Encoding Soluble flt-1 Vascular Endothelial Growth Factor Receptor , 2002, Pancreas.

[35]  Y. Taketani,et al.  Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. , 2002, Cancer research.

[36]  H. Beug,et al.  TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. , 1996, Genes & development.

[37]  R. Whitehead,et al.  A new colon carcinoma cell line (LIM1863) that grows as organoids with spontaneous differentiation into crypt-like structures in vitro. , 1987, Cancer research.

[38]  M. Horton,et al.  Apoptosis induced by inhibition of intercellular contact , 1994, The Journal of cell biology.

[39]  S. Soker,et al.  Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. , 2001, The American journal of pathology.